Brief: Absci Announces First Participants Dosed In Phase 1/2A Headline Trial
Dec 4 (Reuters) - Absci Corp ABSI.O: ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1/2A HEADLINE™ TRIAL OF AI-DESIGNED ANTIBODY ABS-201™ FOR ANDROGENETIC ALOPECIA ABSCI CORP: INTERIM DATA ANTICIPATED IN SECOND HALF OF 2026 ABSCI CORP - PHASE 2 DEVELOPMENT OF ABS-201 IN ENDOMETRIOSIS PLANNED FOR Q4 2026 Source text: ID:nGNXR58y Further company coverage: ABSI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbSci
See all newsAbsci Corp reports results for the quarter ended September 30 - Earnings Summary
Brief: Absci Corp Files For Mixed Shelf Size Not Disclosed - SEC Filing
Absci Q3 revenue misses estimates, net loss widens on R&D spends
Focus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave